Associated Press, January 5, 2012. AP News covers NRC’s letter to Dr. Margaret Hamburg, FDA Commissioner, on the missing data for breast implants.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
Consumer Group Questions Review of Breast Implants
AP News, January 5, 2012. Consumer safety advocates are questioning the Food and Drug Administration about incomplete and seemingly erroneous data used to support the safety of silicone breast implants in an agency review last year.
Read More »New Review Shows FDA is Missing Crucial Safety Information on Breast Implants
January 5, 2012. As the scandal about dangerous breast implants spreads to many countries across the globe, the FDA can be proud that the agency did not approve implants made by that company, France’s Poly Implant Prothese (PIP).
Read More »Insight: Breast Implant Scandal Shows Regulators in Dark on Risk
Reuters, December 29, 2011. With the scandal surrounding France’s Poly Implant Prothese (PIP), questions arise whether there should be a national or worldwide breast implant registry.
Read More »With Doubts, FDA Panel Votes for Yaz and Related Contraceptives
National Public Radio, December 9, 2011. Doubts have been growing about Yasmin, Yaz and their sister contraceptives for several years now. And those doubts reached full flower at a Food Drug Administration advisory panel on Thursday.
Read More »